News
PALI
0.4481
-1.90%
-0.0087
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 6d ago
BRIEF-Palisade Bio Files For Offering Of 3.9 Mln Shares By Selling Securityholders
reuters.com · 06/14 11:29
Palisade Bio to Present at the 2022 BIO International Convention
In-person presentation on Monday, June 13th at 1:45 PM PTCARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complicatio...
GlobeNewswire · 06/07 12:30
BRIEF-Palisade Bio Reports Qtrly Loss Per Share $0.26
reuters.com · 05/13 13:08
Palisade Bio GAAP EPS of -$0.26 beats by $0.02
Palisade Bio press release (NASDAQ:PALI): Q1 GAAP EPS of -$0.26 beats by $0.02. As of March 31, 2022, the Company had cash and cash equivalents of $6.6 million Shares -3.29%
Seekingalpha · 05/13 13:04
-- Earnings Flash (PALI) PALISADEBIO Posts Q1 Loss $-0.26
MT Newswires · 05/13 09:11
Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires
CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new ...
GlobeNewswire · 05/10 21:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 05/09 12:18
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.
Benzinga · 05/09 10:27
BRIEF-Palisade Bio Announces $2 Mln Registered Direct Offering
reuters.com · 05/06 13:46
Palisade Bio to raise $2M in stock offering
Palisade Bio (NASDAQ:PALI) trades 11.3% down premarket after it entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3.65M shares at
Seekingalpha · 05/06 12:47
Palisade Bio Announces $2M Registered Direct Offering
Palisade Bio, Inc. (NASDAQ:PALI) (the "Company" or "Palisade Bio"), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced
Benzinga · 05/06 12:30
Palisade Bio Announces $2.0 Million Registered Direct Offering
CARLSBAD, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company” or “Palisade Bio”), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced tha...
GlobeNewswire · 05/06 12:30
Palisade Bio gets Chinese regulatory nod to start late-stage study for lead candidate
Clinical stage biotech Palisade Bio (NASDAQ:PALI) and co-development partner Newsoara Biopharma have got regulatory clearance in China to proceed with their phase 3 trial to evaluate LB1148 for accelerated return
Seekingalpha · 05/05 14:24
BRIEF-Palisade Bio And Newsoara Receive NMPA Clearance To Commence Phase 3 Clinical Trial In China
reuters.com · 05/05 12:39
Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery
NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study Newsoara to fully fund Phase 3 program in China Under the Co-Development Agreement, co...
GlobeNewswire · 05/05 12:30
Palisade Bio Provides Business Outlook And Highlights Expected Near-Term Pipeline Advancements
Palisade Bio (NASDAQ:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provided a business outlook and outlined its
Benzinga · 05/02 12:37
Palisade Bio to Participate in the Virtual Investor Management and KOL Roundtable Event
Live moderated video webcast discussion among members of Management and a renowned Key Opinion Leader on Tuesday, May 3rd at 10:00 AM ETCARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical com...
GlobeNewswire · 04/29 12:05
4 Penny Stocks Insiders Are Buying: Heritage Global, Palisade Bio And More
US crude oil futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in...
Benzinga · 04/01 13:12
Companies Like Palisade Bio (NASDAQ:PALI) Could Be Quite Risky
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 03/30 19:47
More
Webull provides a variety of real-time PALI stock news. You can receive the latest news about Palisade Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About PALI
Palisade Bio, Inc, formerly Seneca Biopharma, Inc., is a biopharmaceutical company. The Company is focused on developing therapies that helps patients with acute and chronic gastrointestinal problems from post-operative digestive enzyme damage. Its product candidate, LB1148, is a Phase III-ready protease inhibitor which is developed to reduce abdominal adhesions and help restore bowel function following surgery. It is engaged in developing oral product candidates to treat conditions driven by protease (intestinal digestive enzymes) escaping the intestines, including surgical problems and inflammatory conditions. Its LB1148 is an oral formulation of a serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.